Tianjin Development Holdings Limited

Tianjin Development Holdings Limited

0.26
USD
+0.02
(+10.62%)
Tianjin Development Holdings Limited
OTC:TJSCF
(OTC Markets)

Recent

price

0.26

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
HKD
3.02
3.29
3.64
4.64
6.38
5.95
5.7
4.21
5.03
4.24
2.76
3.3
3.45
3.11
3.13
2.98
- -
Revenue per Share
0.44
0.41
0.39
0.66
0.69
0.52
0.48
0.46
0.44
0.43
0.27
0.44
0.33
0.59
0.51
0.4
- -
Basic EPS, GAAP
0.16
-0.18
-0.1
-0.08
-0.77
-0.03
-0.32
0.12
-0.84
-0.72
0.12
-0.55
0.04
-0.42
-0.85
-0.03
- -
Free Cash Flow per Basic Share
- -
- -
- -
0.09
0.24
0.13
0.14
0.13
0.14
0.13
0.13
0.1
0.14
0.13
0.22
0.2
- -
Dividend per Share
8.32
8.98
9.42
9.39
9.77
9.49
9.23
10.23
10.55
10.59
11.43
12.02
11.2
11.68
11.74
12.14
12.14
Book Value per Share
8.27
8.72
8.59
8.67
8.93
8.84
8.75
9.69
10.19
10.01
10.83
11.78
10.99
11.49
11.42
11.83
11.83
Tangible Book Value per Share
1,067
1,067
1,067
1,067
1,067
1,071
1,073
1,073
1,073
1,073
1,073
1,073
1,073
1,073
1,073
1,073
1,073
Basic Weighted Avg Shares
3,223
3,517
3,890
4,952
6,814
6,369
6,110
4,518
5,392
4,549
2,960
3,541
3,705
3,338
3,359
3,196
- -
Sales/Revenue/Turnover
0.13
-3.95
-4.3
-8.71
-1.95
-2.07
0.63
-3.19
2.92
1.97
-8.12
-4.57
0.23
3.23
-2.94
-2.46
- -
Operating Margin (%)
130
82
105
164
254
261
260
307
306
225
218
223
193
204
186
203
- -
Depreciation Expense
474
437
413
704
737
562
515
489
472
461
294
470
358
636
548
428
- -
Net Income, GAAP
10.39
17.77
10.71
8.13
9.61
9.23
7
6.04
9.89
10.84
16.56
6.13
9
9.24
9.57
9.17
- -
Effective Tax Rate (%)
14.71
12.43
10.62
14.22
10.82
8.83
8.43
10.82
8.75
10.14
9.95
13.28
9.67
19.04
16.31
13.39
- -
Profit Margin (%)
2,892
4,525
4,345
2,984
5,470
2,527
4,506
5,737
4,970
6,104
6,760
5,421
6,953
7,831
5,998
5,990
5,990
Working Capital
- -
1,988
1,994
154
2,665
87
1,859
1,857
- -
1,993
2,003
9
1,575
1,716
38
1,750
1,750
LT Debt
9,407
10,182
10,906
13,621
14,102
13,782
13,377
14,747
16,101
15,892
17,041
17,876
16,429
17,513
17,455
17,922
17,922
Total Equity
-6.02
-0.9
-0.76
0.32
0.08
-1.42
-0.39
-1.19
1.95
-0.02
-1.18
-0.85
-0.05
1.78
1.52
-0.36
- -
Return on Invested Capital (%)
4.22
3.27
3.02
4.53
3.72
2.8
2.62
2.78
0.83
1.93
1.83
1.99
1.5
2.07
2.08
0.95
- -
Return on Capital (%)
5.35
4.73
4.21
7.01
7.21
5.46
5.13
4.68
4.23
4.07
2.49
3.74
2.88
5.18
4.36
3.34
- -
Return on Common Equity (%)

Capital Structure

HKD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
1,976
1,953
247
LT Borrowings
25
31
1,742
LT Finance Leases
14
9
8
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,073
1,073
1,073
Market Capitalization
2,143
1,958
- -

Working Capital

HKD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
10,492
9,574
9,003
Cash, Cash Equivalents & STI
7,952
6,676
6,557
Accounts Receivable, Net
1,158
1,340
1,251
Inventories
305
325
344
Total Current Liabilities
4,494
4,579
3,013
Payables & Accruals
- -
- -
- -
ST Debt
1,976
1,953
247
Deferred Revenue
- -
- -
- -

Growth Rates

HKD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.82%
1.15%
2.67%
Free Cash Flow
-189.88%
-359.6%
-96.43%
Net Income, GAAP
2.23%
15.53%
-21.92%
Sales/Revenue/Turnover
-5.12%
2.03%
-4.86%
Total Cash Common Dividend
6.59%
14.08%
-8.29%

Semi-annual Revenue

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
3,338
2024
- -
- -
3,359
2025
- -
- -
3,196

Semi-annual Earnings Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.59
2024
- -
- -
0.51
2025
- -
- -
0.4

Semi-annual Dividends Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.13
2024
- -
- -
0.22
2025
- -
- -
0.2
Business
Tianjin Development Holdings Limited is an investment holding company principally engaged in utilities supply and diversified operations including pharmaceuticals, hotels, electrical and mechanical engineering, port services, and elevators and escalators in the People's Republic of China. The company operates through six main segments: the Utilities segment distributes electricity with an installed transmission capacity of approximately 996,000 kVA, water with a daily supply capacity of 325,000 tonnes, heat, and thermal power via approximately 549 kilometres of steam transmission pipelines, 120 processing stations, and a daily steam distribution capacity of approximately 30,000 tonnes to industrial, commercial, and residential customers; the Pharmaceutical segment, including Lisheng Pharmaceutical (002393.SZ) and Yiyao Printing, manufactures and sells pharmaceutical products, provides research and development services, and offers design, manufacture, and printing for pharmaceutical packaging as well as other paper-based packaging materials; the Hotels segment manages properties such as Courtyard by Marriott Hong Kong; the Electrical and Mechanical segment manufactures and sells presses, mechanical and hydroelectric equipment, and large-scale pump units; the Port Services segment provides container and cargo handling services through its listed associate Tianjin Port Development Holdings Limited (3382.HK), in which it holds a 21% stake accounted for using the equity method; and the Elevators and Escalators segment manufactures and sells elevators and escalators via its 16.55% stake in Otis Elevator (China) Investment Company Limited, also accounted for using the equity method. Incorporated on May 9, 1997 and headquartered at Suites 7-13, 36th Floor, China Merchants Tower, 168-200 Connaught Road Central, Hong Kong, the company primarily serves markets in China and is a subsidiary of Tsinlien Group Company Limited, with a workforce of approximately 2,740 employees. Recent developments include the renewal of key connected transaction agreements with Tianjin TEDA Investment Holding Co. Ltd. in November 2024 for water testing services, steam purchases, and other utilities-related arrangements effective from January 2025 for three years, pending shareholder approval at an extraordinary general meeting; a unit's entry into a partnership in September 2025 to establish a RMB500 million fund; and the acquisition of Jiangxi Qingchun Kangyuan Pharmaceutical Co., Ltd. and its subsidiary during the first half of 2025, alongside property, plant, and equipment additions of HK$25.93 million in the interim period ended June 30, 2025 to support business expansion.